^
Association details:
| Biomarker: | RANBP2-ALK rearrangement + TNFRSF8 expression |
|---|---|
| Cancer: | Sarcoma |
| Drug: | Adcetris (brentuximab vedotin) (Microtubule inhibitor, CD30-targeted antibody-drug conjugate) |
| Direction: | Resistant |
Evidence:
Source:
Title:
CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma
Published date:
07/20/2020
Excerpt:
Epithelioid inflammatory myofibroblastic sarcoma (eIMS)...Xenografts were validated by confirmation of RANBP2-ALK rearrangement, perinuclear ALK localisation and CD30 expression. Although brentuximab-vedotin (BV) demonstrated single-agent activity, tumours regrew during BV therapy. BV resistance was associated with reduced CD30 expression and induction of ABCB1.
DOI:
10.1038/s41416-020-0996-2
